Cognition Therapeutics, Inc. Investing Cash Flow
Cognition Therapeutics, Inc. (CGTX) reported Investing Cash Flow of -$20.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-07
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was -$1.00K.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2024-09-30 was $0.00.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2023-12-31 was -$30.00K.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2023-09-30 was -$58.00K.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $9.00K.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$4.00K.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$147.00K.
- Cognition Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$171.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.00K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $9.00K 10-K · filed 2026-03-26 | |||
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.00K derived: sum of 2 quarters · filed 2026-03-26 | -$4.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$3.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$88.00K derived: sum of 2 quarters · filed 2025-03-20 | -$106.00K derived: sum of 3 quarters · filed 2025-03-20 | -$147.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$76.00K derived: sum of 2 quarters · filed 2024-11-13 | -$117.00K 10-Q · filed 2024-11-13 | -$127.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$59.00K 10-Q · filed 2024-08-08 | -$69.00K derived: sum of 3 quarters · filed 2024-08-08 | -$92.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$41.00K 10-Q · filed 2024-05-07 | -$51.00K derived: sum of 2 quarters · filed 2024-05-07 | -$74.00K derived: sum of 3 quarters · filed 2024-05-07 | -$78.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$33.00K derived: sum of 2 quarters · filed 2024-03-26 | -$37.00K derived: sum of 3 quarters · filed 2024-03-26 | -$171.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$27.00K derived: sum of 2 quarters · filed 2023-11-02 | -$161.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$138.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$134.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$27.00K 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$10.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$10.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |